Field Diagnostics Pillar

Field Diagnostics Equipment

Global Health Equipment Review·Field Series·Evidence Desk·Peer-reviewed in spirit · Educational

Rapid tests, portable microscopy, point-of-care analyzers, and HIV field testing — evaluated where it actually matters, in heat, dust, and intermittent power. Graded for the field, not the catalog, and read as the first link in the surveillance chain.

Read the RDT guide Portable microscopy

Plate II

Fig. — field plate

Figure. Engraved reference plate — evaluating equipment on field resilience, not lab-bench ideals.

Editorial Position

Diagnosis is the first link in the surveillance chain

A diagnostic result in a low-resource setting is rarely just a clinical decision — it is also a data point. The malaria RDT read at a health post in the Sahel, the dengue NS1 line interpreted in a flooded clinic, the CD4 count run at the only visit a patient may make, the AFB smear counted under a field microscope: each feeds the case definitions that public-health programmes depend on to detect outbreaks early and to monitor whether treatment is working.

That is why International Health evaluates field diagnostics against three axes the manufacturer datasheet usually omits: accuracy under real storage conditions, ruggedness against transport and climate, and operability by a non-laboratory user. A test that performs flawlessly in a reference lab but degrades after a week above 30 °C in a cool box is, for our readership, a different product entirely. The four guides under this pillar apply the same framework to four distinct equipment classes.

How this connects to cold chain

From the review desk

The four guides under this pillar

Four equipment classes carry most of the diagnostic burden in outbreak and routine global-health work. Each is reviewed on its own terms, against the same field-first framework.

04entries in this issue

Review criteriaBy which we judge field gear

01Criterion

4

Diagnostic equipment classes reviewed under this pillar

02Criterion

30 °C+

Storage threshold where many field assays begin to lose sensitivity

03Criterion

WHO PQ

Prequalification benchmark we cite, not replace

04Criterion

0

Named-product endorsements or sponsored placements

Standards of the desk

Our field-equipment review method

Our field-diagnostic evaluation framework

Every device under this pillar is graded against the same four-stage method so reviews stay comparable across categories — from a lateral-flow strip to a viral-load cartridge.

01Step
1. Specification against intended use
We start from the case definition. A test meant for community case management is judged differently from a confirmatory assay. Sensitivity and specificity targets are anchored to the published WHO and programme thresholds for that condition — for HIV, to the sequential-algorithm benchmarks rather than to any single test.
02Step
2. Cold chain and stability burden
We document the real storage envelope: stated temperature range, excursion tolerance, and whether reagents or cartridges add a cold-chain dependency — sometimes a second cold chain on top of the vaccine one — that a passive cool box can realistically sustain in transit.
03Step
3. Ruggedness and operability
Dust ingress, humidity, drop survival, power source, and the cognitive load on a non-laboratory operator. A faint line that trained readers miss, or a quantitative result an operator cannot validate, is an operability failure, not just a sensitivity one.
04Step
4. Surveillance fit
Can the result be captured, reported, and trusted as a notifiable data point? We assess result legibility, batch traceability, and how cleanly the device output maps onto an outbreak or treatment-monitoring surveillance workflow.

Method of review

ArticleField Series

The figures behind the field-first framework

The framework above is not abstract caution; it is a response to documented, quantified failure modes. Three numbers from the WHO and the peer-reviewed literature explain why we grade as we do.

≥5% — the threshold that retires an antigen target

Most P. falciparum rapid tests detect histidine-rich protein 2 (HRP2). Parasite strains carrying deletions of the pfhrp2 and pfhrp3 genes produce no HRP2, so an HRP2-only test reads negative in a genuinely — sometimes severely — infected patient. WHO recommends switching a programme to a non-HRP2 (pLDH-based) test once these deletions cause ≥5% of RDTs to return false negatives. By 2023 the WHO Malaria Threat Maps recorded pfhrp2/3 deletion reports in 40 of 47 countries surveyed, with false-negative rates reaching as high as 80% in the worst-affected settings of the Horn of Africa. A diagnostic platform graded only on its clean-strain sensitivity hides this entirely — which is why our reviews treat antigen-deletion coverage as a named criterion.

30°C+ — where the datasheet quietly stops applying

Published sensitivity and specificity figures are generated under controlled storage with trained readers. Many lateral-flow assays carry a labelled storage ceiling around +30°C, yet a closed diagnostics box on a tarmac airstrip can pass +40°C within hours. A test that meets its specification in a reference laboratory does not necessarily meet it after three weeks at ambient at a health post. We treat that real-world degradation as part of accuracy, not a footnote to it — and recommend a temperature logger dedicated to the diagnostics box, separate from the vaccine cold chain.

The window period — a blind spot no engineering closes

Every serological test has an interval after infection during which its target marker has not yet risen above the detection threshold. Antibody-only HIV tests have the longest window; fourth-generation tests that also detect p24 antigen shorten it but do not close it. Likewise, a dengue NS1 antigen test is informative only across roughly days one to seven of fever — a day-six negative is uninformative, not reassuring. Timing, not just accuracy, decides what a result means; our category guides make the window a first-order consideration, not a caveat.

End of section

Plate II

Fig. — field plate

Figure. Engraved reference plate — evaluating equipment on field resilience, not lab-bench ideals.

Honest trade-offs

What field diagnostics cannot do, and where referral wins

An editorial framework that only celebrates near-patient testing would be dishonest. The decentralisation these devices offer is genuine and often decisive — a confirmed case while the patient is still present, a result that does not depend on a referral sample surviving a round trip. But each class has a hard limit it is important to state plainly.

A rapid test answers presence or absence, not quantity: it cannot stage disease, measure parasite density to guide treatment, or monitor a viral load. A field microscope can speciate and quantify, but only as well as its consumables, its illumination, and the technician's training allow — and it has no answer for drug resistance. A point-of-care analyzer returns an authoritative-looking number that, without field quality control, can be a black box producing wrong values with false confidence; and several add a second cold chain that can quietly outweigh the logistical saving they were bought to deliver. The honest conclusion is that where a programme's true bottleneck is access or loss-to-follow-up, near-patient testing earns its place; where the bottleneck is analytical rigour and a reference laboratory is reachable, a strengthened referral pathway is often the better investment. Saying which applies to a given deployment is the work these guides try to do.

How we set our editorial standards

Correspondence

Queries to the desk

06 entries on file

Q1.Why grade diagnostics on ruggedness rather than just accuracy?

Because in field settings the two are inseparable. Published sensitivity figures are generated under controlled storage and trained readers. A device that meets those figures only inside a reference lab does not meet them at a health post that has stored it at ambient temperature for three weeks. We treat real-world degradation as part of accuracy, not a footnote to it.

Q2.How does field diagnostics connect to public health surveillance?

Diagnosis produces the confirmed cases that drive case counts, outbreak thresholds, and response triggers — and the CD4 and viral-load trends that show whether treatment programmes are working. If the diagnostic layer is unreliable — false negatives during a dengue surge, missed AFB smears, an unverified analyzer reading — the surveillance signal is corrupted upstream. We review the equipment and the workflow together.

Q3.Do you recommend specific diagnostic brands?

No. This is an editorial authority platform, not a procurement broker. We frame the decision criteria, cite WHO prequalification and the relevant testing strategies, and explain trade-offs. We do not name preferred products, quote prices, or accept sponsorship. The four category guides — RDTs, microscopes, analyzers, and HIV kits — teach the evaluation, not a shopping list.

Q4.What about point-of-care analyzers that need their own cold chain?

That dependency is exactly what our framework surfaces. Several CD4 and viral-load platforms carry cartridges with their own temperature limits, effectively adding a second cold chain on top of the vaccine one. We flag that burden explicitly so logisticians can weigh it against centralised lab referral before committing to a platform — the analyzer guide treats it as the first question to settle.

Q5.What is the HRP2 deletion problem and why does it change which test to buy?

Most P. falciparum rapid tests detect the HRP2 antigen. Parasite strains with pfhrp2/pfhrp3 gene deletions make no HRP2, so an HRP2-only test reads negative in a truly infected patient. WHO advises switching to a non-HRP2 (pLDH-based) combination test once deletions cause 5% or more false negatives locally, and deletions have now been reported in the large majority of malaria-endemic countries surveyed. The procurement consequence is direct: in regions with known or suspected deletions, specify a combination malaria RDT that also targets pLDH, and pair it with a rule that escalates clinical-malaria-with-negative-RDT to microscopy. The rapid-diagnostic-tests guide covers the selection in detail.

Q6.Where should a programme draw the line between rapid testing and microscopy?

They are sequential roles, not alternatives. The rapid test triages at the point of care — fast, instrument-free, carrying the bulk of routine case detection. The microscope confirms and quantifies: it speciates the parasite, measures parasite density to guide treatment, catches the low-density and antigen-deletion cases the strip misses, and serves as the reference standard that audits RDT performance over time. The error to avoid is over-relying on the strip in settings with deletions or low-density infections, or burdening a microscopist with slides a reliable RDT could have triaged. Our microscope guide maps the handoff step by step.

From the editorial desk

Bring field-tested judgment to your next diagnostic decision

Our editors review global-health equipment for the conditions you actually work in. Share a diagnostic question, a deployment context, or a category you want assessed — and read the four category guides for the detailed evaluations behind this pillar.

Contact the editors

Field Diagnostics Equipment

Diagnosis is the first link in the surveillance chain

The four guides under this pillar

Malaria & Dengue Rapid Tests (RDTs)

Portable Field Microscopes

Point-of-Care Analyzers

HIV Field Testing Kits

Our field-diagnostic evaluation framework

1. Specification against intended use

2. Cold chain and stability burden

3. Ruggedness and operability

4. Surveillance fit